RT Journal Article
SR Electronic
T1 Interpretable Machine Learning-Based Clinical Predictive Model for Early Readmission in Patients with Cardiogenic Shock
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.08.24310102
DO 10.1101/2024.07.08.24310102
A1 Tieliwaerdi, Xiarepati
A1 Abuduweili, Abulikemu
A1 Mutabi, Erasmus
A1 Manalo, Kathryn
A1 Lander, Matthew
YR 2024
UL http://medrxiv.org/content/early/2024/07/09/2024.07.08.24310102.abstract
AB Background/Purpose Cardiogenic shock (CS) is a critical condition characterized by low cardiac output leading to end-organ hypoperfusion and often multisystem organ failure, affecting up to 50,000 people annually in the United States. Acute myocardial infarction (AMI) is the primary cause, responsible for 81% of CS cases. Despite advancements in reperfusion therapies improving survival, in-hospital mortality remains high at 40%-67%, with 18.6% of survivors readmitted within 30 days. Traditional methods struggle to quantify and process the complex interactions among various risk factors, making prediction of readmissions challenging. Machine learning (ML) offers a promising solution by capturing intricate patterns and non-linear relationships among numerous variables. This study aims to develop an ML-based prediction model for 7-day and 30-day readmission rates in CS patients using the 2019 National Readmission Database (NRD). Additionally, the study utilizes SHapley Additive exPlanations (SHAP) to interpret the outcomes of the applied machine learning methods.Method We conducted a retrospective study using the NRD for 2019. Index hospitalizations were identified by non-elective admissions with a primary ICD-10 diagnosis of cardiogenic shock. Exclusions included patients under 18, missing length of stay or days to event data, and same-day transfers. The primary outcome was readmission within 7- and 30-days post-discharge. Welch’s t-test compared continuous variables. Various ML models were evaluated for their predictive performance, and SHAP values were used to interpret the most influential features.Results The study included 97,653 adults hospitalized for CS, with a mean age of 65.8 years and 38.4% being female. The in-hospital mortality rate was 33.7%. Among 51,976 index hospitalizations, 8.3% were readmitted within 7 days, and 21.02% within 30 days. Significant predictors of higher readmission rates included younger age, lower income, Medicaid insurance, CKD3, drug abuse, chronic pulmonary disease, PHTN, depression, leukemia, lymphoma, discharge against medical advice, and certain hospital characteristics. The FT-Transformer (a specialized deep neural network approach for tabular data) model achieved the highest AUCs of 0.76 and 0.78 for 7-day and 30-day readmissions, respectively, outperforming traditional methods like Logistic Regression (AUCs: 0.60 and 0.63).SHAP analysis revealed a wide array of features contributing to readmission predictions at both the population and individual levels. For the general population, the top features included APRDRG, DRG_NoPOA, age, chronic kidney disease, length of stay, number of ICD-10 codes, and disposition at discharge. In contrast, for an individual patient, the most influential feature for predicting 7-day readmission may differ, though there are some overlaps. This highlights the potential of personalized medicine, where individual risk factors are weighted differently compared to the general population, providing tailored insights for targeted interventions.Conclusion This study demonstrates that advanced ML models, particularly the FT-Transformer and Random Forest, significantly outperform traditional methods in predicting readmissions in CS patients. The use of SHAP values enhances the interpretability of these models, providing actionable insights for healthcare providers. The differentiation between general population feature contributions and individual-specific factors underscores the importance of personalized medicine. By understanding individual risk profiles, healthcare providers can implement more precise and effective interventions, ultimately aiming to reduce readmissions and optimize healthcare outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were from National readmission database 2019, here is the link to the related website: https://hcup-us.ahrq.gov/db/nation/nrd/Introduction_NRD_2019.jsp#:~:text=Unweighted%2C%20the%20NRD%20contains%20approximately,national%20readmissions%20for%20all%20payers.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.